The FDA responds to the vaccine of a dose against Johnson & Johnson’s COVID-19 and provided a clearance of its use in the United States

The vacancy of a single dose of Johnson & Johnson otorga protection against COVID-19, following the analysis carried out by the markets by the EUEU regulators which are the bases for a final decision on a new injection easier to use to help .

The Scientific Offices of the Food and Drug Administration (FDA) confirm that, in general, the vaccine has a 66% reduction efficiency in the prevention of moderate COVID-19. The agency also says that the injection of J&J -which should help to accelerate the vacancies to require only a dose in place of safe use.

The firefighters, the independent assessors of the debating agency will try their most solid solids as to recommend the tan hope vacuna. Armed with this assessment, it is hoped that the FDA will make a final decision in the next few days.

J&J has tried its single dose option in 44,000 people from the United States, Latin America and South Africa. Given that in different countries there are different versions of mutated viruses, the researchers analyze the geographical results. J&J has previously announced that the vacancy will work better in the United States, with a 72% efficiency against the moderate COVID-19, compared to 66% in Latin America and 57% in South Africa.

Aun así, en todos los países fue very effective against the most severe syndromes, and the first results of the study show that no hospitalizations were killed within 28 posterior days of evacuation.

Although general efficacy figures can suggest that J & J’s candidate is not as potent as those of its dose competitors, all COVID-19 vacancies in the world have tried different shapes, which makes the comparisons impossible. Although no series surprising that a dose results in a little more debilitating than two, the political leaders decide if there is an acceptable acceptance to ensure that more people are evacuated more quickly.

J&J is on the verge of converting to the first option of a dose in the world until the principles of this month, Mexico announced that it will use a version of a dose of the Chinese company CanSino.

The United States Vacation Campaign has the most to offer in terms of hope, overcoming logistical and meteorological problems, including breaking down more than 500,000 deaths related to the virus. Hasta now, 65 million stadiums have received at least one dose of the vaccine manufactured by Pfizer or Moderna, vacancies that require doses with varying degrees of differentiation for complete protection.

If the FDA authorizes the use of the J&J vaccine in EEUU, it will not significantly increase the summit of intermediate vaccines. It is hoped that only a few million dose doses will be listed for this week in the first week. Without embargo, J&J told Congress this week that it would hope to add 20 million for the March finals and 100 million for the year.

European regulatory bodies and the World Health Organization are also studying the J&J vaccine. All over the world, the company claims to produce thousands of millions of doses for the finals of this year.

(With AP information)

MORE ABOUT THIS THEME: